Profile

Aaron K. Olson, MD

Aaron K. Olson, MD

Cardiology

On staff since July 2006

Academic Title: Assistant Professor, Division of Cardiology, Department of Pediatrics

Research Center: Center for Developmental Therapeutics

"I go to work each day striving to make new discoveries in the basic science mechanisms controlling cardiovascular disease in children. I hope to translate these discoveries into new therapies for pediatric patients. "

Aaron Olson, MD, is an attending physician at Seattle Children’s Hospital and Assistant Professor in the Department of Pediatrics at the University of Washington School of Medicine. His clinical work is in general pediatric cardiology. His research interests include pharmacological clinical trials and metabolic regulation in the heart.

Overview

Board Certification(s)

Pediatrics
Pediatric Cardiology

Medical/Professional School

University of Minnesota , Minneapolis
University of Minnesota - Duluth School of Medicine, Duluth

Residency

Pediatrics, University of Chicago , Chicago

Fellowship

Pediatric Cardiology, University of Iowa Hospitals and Clinics, Iowa City
Pediatric Cardiology, University of Iowa Hospitals and Clinics, Iowa City

Clinical Interests

Neonatal heart disease

Lab URL

http://www.seattlechildrens.org/research/developmental-therapeutics/labs-programs/olson-lab/

Research Focus Area

Cardiac Metabolism, Kawasaki Disease, Cardiac Hypertrophy, Genetic Cardiovascular Disease

Publications

  • Choueiter NF, Olson AK, Shen DD, Portman MA
    Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease.
    The Journal of pediatrics , 2010 Dec. : 960-966.e1
  • Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S
    Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
    Circulation , 2010 Sept. 14 : S224-33
  • Portman MA, Slee A, Olson AK, Cohen G, Karl T, Tong E, Hastings L, Patel H, Reinhartz O, Mott AR, Mainwaring R, Linam J, Danzi S
    Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary Bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.
    Circulation , 2010 Sept. 14 : S224-33
  • Choueiter NF, Olson AK, Shen DD, Portman MA
    Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease.
    The Journal of pediatrics , 2010 July 26
  • Olson AK, Hyyti OM, Cohen GA, Ning XH, Sadilek M, Isern N, Portman MA
    Superior cardiac function via anaplerotic pyruvate in the immature swine heart after cardiopulmonary bypass and reperfusion.
    American journal of physiology. Heart and circulatory physiology , 2008 Dec. : H2315-20
  • Hyyti OM, Olson AK, Ge M, Ning XH, Buroker NE, Chung Y, Jue T, Portman MA
    Cardioselective dominant-negative thyroid hormone receptor (Delta337T) modulates myocardial metabolism and contractile efficiency.
    American journal of physiology. Endocrinology and metabolism , 2008 Aug. : E420-7
  • Olson AK, Protheroe KN, Scholz TD, Segar JL
    Activation of the mitogen-activated protein kinases and Akt in response to pulmonary artery banding in the fetal sheep heart is developmentally regulated.
    Neonatology , 2008 : 145-52
  • Olson AK, Protheroe KN, Segar JL, Scholz TD
    Mitogen-activated protein kinase activation and regulation in the pressure-loaded fetal ovine heart.
    American journal of physiology. Heart and circulatory physiology , 2006 Apr, : H1587-95
  • Olson AK, Protheroe KN, Scholz TD, Segar JL
    The mitogen-activated protein kinases and Akt are developmentally regulated in the chronically anemic fetal sheep heart.
    Journal of the Society for Gynecologic Investigation , 2006 Apr, : 157-65

Presentations

Presentations Title Event Location Date
Metabolic Substrate Utilization During C-Myc Induced Cardiac Hypertrophy July 1, 2009

Research Funding

Grant Title Grantor Amount Award Date
The Marfan Trial- a Trial of Beta Blocker Therapy (Atenolol) vs. Angiotensin II Receptor Blocker Therapy (Losartan) in individuals with Marfan syndrome (MFS) National Institute of Health $unknown Feb. 1, 2008
Role of Fcgamma Receptor Polymorphisms in Determining IVIG Response in Kawasaki Disease Thrasher Foundation Jan. 1, 2008